Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
10.04
+0.96 (10.57%)
At close: Nov 21, 2025, 4:00 PM EST
10.08
+0.04 (0.40%)
Pre-market: Nov 24, 2025, 5:37 AM EST
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $9.10M in the quarter ending September 30, 2025, a decrease of -9.00%. This brings the company's revenue in the last twelve months to $38.20M, up 22.04% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$38.20M
Revenue Growth
+22.04%
P/S Ratio
0.69
Revenue / Employee
$876,556
Employees
900
Market Cap
527.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
| Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
| Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
| Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
| Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
| Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
| Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
| Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
| Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
| Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
| Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
| Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
| Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
| Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
| Dec 31, 2005 | 130.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EBS News
- 6 days ago - Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access - GlobeNewsWire
- 11 days ago - Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors - GlobeNewsWire
- 17 days ago - Emergent BioSolutions: Solid Q3, Expecting Better Days To Come - Seeking Alpha
- 25 days ago - Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Emergent BioSolutions Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 27 days ago - Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 - GlobeNewsWire
- 2 months ago - Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone - GlobeNewsWire